Matthew Lang's most recent trade in Metsera Inc. was a trade of 46,875 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on May 20, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Metsera Inc | Matthew Lang | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2025 | 46,875 | 46,875 | - | - | Stock Option (Right to Buy) | |
| Lyell Immunopharma Inc | Lang Matthew | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2025 | 450,000 | 450,000 | - | - | Option (right to buy) | |
| Lyell Immunopharma Inc | Lang Matthew | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2025 | 112,500 | 162,500 | - | 0 | Common Stock | |
| Lyell Immunopharma Inc | Lang Matthew | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2025 | 56,250 | 56,250 | - | - | Option (right to buy) | |
| Lyell Immunopharma Inc | Matthew Lang | Chief Business Officer | 09 Feb 2024 | 500,000 | 500,000 | - | - | Option (right to buy) | ||
| Lyell Immunopharma Inc | Matthew Lang | Chief Business Officer | 09 Feb 2024 | 50,000 | 50,000 | - | 0 | Common Stock |